Trial site
Neurology Associates PA
Maitland, Florida 32751, United StatesNot linked to an institution yet
- 19running trials
- 6closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 24 trials
- Phase 44 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Active, not recruiting14 trials
- Completed5 trials
- Recruiting5 trials
- Terminated1 trial
- Lead sponsor
- Novartis Pharmaceuticals9 trials
- Hoffmann-La Roche6 trials
- argenx3 trials
- NeuroDerm Ltd.2 trials
- Genentech, Inc.1 trial
- and 4 more
Running trials
Recruiting
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
NCT07609719· Phase 4· Genentech, Inc.· Source
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source
Active, not recruiting
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· Phase 3· Novartis Pharmaceuticals· Source
Contact: Mary Grace Remedio
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· Phase 3· Novartis Pharmaceuticals· Source
Contact: Nicole Perovic
Active, not recruiting
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
NCT07667322· Phase 1· Hoffmann-La Roche· Source
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source
Active, not recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279· Phase 3· argenx· Source
Active, not recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552· Phase 3· argenx· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
NCT05090371· Phase 4· Novartis Pharmaceuticals· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
NCT04006210· Phase 3· NeuroDerm Ltd.· Source
Active, not recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
NCT02726386· Phase 2· NeuroDerm Ltd.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error